

	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	
Hall Building	No.1 (Hall C 4F)	Symposium 1 What's new in lymphoma classification? Chairs : Hirokazu Nagai, Kennosuke Karube			Presidential Symposium Cutting edge for transplantation and cellular therapy Chair : Takanori Teshima Speakers : Luca Vago, Michel Sadelain	LS1-1 Symbio Pharmaceuticals Limited	Opening Ceremony	Presidential Lecture	Symposium 3 Current status and future direction of treatment in multiple myeloma Chairs : Dai Maruyama, Michiko Ichii				Reception for all the participants (Rose, 3F, Tokyo Kaikan) (18 : 15~)
	No.2 (Hall B7(1) 7F)	Symposium 2 The basis of erythropoiesis Chairs : Takahiro Suzuki, Yasutaka Ueda				LS1-2 Novartis Pharma K.K.			Symposium 4 A new era of leukemia developing into international collaborative research Chairs : Atsushi Manabe, Motohiro Kato				
	No.3 (Hall B7(2) 7F)	EL1-3-1	EL1-3-2	EL1-3-3		LS1-3 Bristol Myers Squibb			EL1-3-4	EL1-3-5	EL1-3-6	ES1-3 Asahi Kasei Pharma Corporation	
	No.4 (Hall B5(1) 5F)	EL1-4-1	EL1-4-2	EL1-4-3		LS1-4 Eisai Co., Ltd.			EL1-4-4	EL1-4-5	EL1-4-6	ES1-4 Pfizer Japan Inc.	
	No.5 (Hall B5(2) 5F)	EL1-5-1	EL1-5-2	EL1-5-3		LS1-5 Janssen Pharmaceutical K.K.			EL1-5-4	EL1-5-5	EL1-5-6	ES1-5 Janssen Pharmaceutical K.K.	
	No.6 (Hall D7 7F)	Asian Joint Panel Discussion Current treatment status of multiple myeloma in Asia Chairs : Shinsuke Iida, Ponlapat Rojnuckarin				LS1-6 Sanofi K.K.			O1-pm1-6	O1-pm2-6		ES1-6 Novartis Pharma K.K.	
	No.7 (Hall D5 5F)	O1-am1-7	O1-am2-7 AML: Clinical Study 2 Chair : Yasuhisa Yokoyama			LS1-7 Meiji Seika Pharma Co., Ltd.			O1-pm1-7	O1-pm2-7 Venetoclax for AML 1 Chair : Senji Kasahara		ES1-7 Sumitomo Pharma Co., Ltd.	
	No.8 (Hall D1 1F)	SETP 1 Bone Marrow Failure		SETP 2 Multiple Myeloma			LS1-8 CSL Behring K.K.		O1-pm1-8	O1-pm2-8		ES1-8 Takeda Pharmaceutical Company Limited	
Glass Building	No.9 (G402 4F)	O1-am1-9 Hematopoietic Regulation 1 Chair : Ayako Nakamura-Ishizu		O1-am2-9		LS1-9 Mundipharma K.K.		O1-pm1-9	O1-pm2-9 MPN: Clinical 2 Chair : Shuichi Shirane		ES1-9 Chugai Pharmaceutical Co., Ltd. / Nippon Shinyaku Co., Ltd.		
	No.10 (G409 4F)	O1-am1-10 MM: Basic Research 1 Chair : Hiroshi Handa		O1-am2-10 CAR-T Cell Therapy: Basics Chair : Chihaya Imai		LS1-10 Swedish Orphan Biovitrum Japan Co., Ltd. / Asahi Kasei Pharma Corporation		O1-pm1-10 ALL: Clinical 1 Chair : Emiko Sakaida	O1-pm2-10		ES1-10 AstraZeneca K.K.		
	No.11 (G502 5F)	O1-am1-11 AML: Genomics and Biology 1 Chair : Yoshikane Kikushige		O1-am2-11 AML: Genomics and Biology 2 Chair : Akihide Yoshimi			LS1-11 Kyowa Kirin Co., Ltd.		O1-pm1-11 MDS: Basic 1 Chair : Hirotsuka Matsui	O1-pm2-11		ES1-11 abbvie GK	
	No.12 (G510 5F)	O1-am1-12 MDS: Clinical 1 Chair : Yuka Sugimoto		O1-am2-12		LS1-12 Fuji Pharma		O1-pm1-12	O1-pm2-12 T Cell Lymphoma and Others: Clinical 1 Chair : Ayako Arai		ES1-12 MSD K.K.		
	No.13 (G602 6F)	O1-am1-13	O1-am2-13 ITP/TTP/Others Chair : Makoto Kaneko			LS1-13 Invivoscribe / LabPMM		O1-pm1-13	O1-pm2-13		ES1-13 Sanofi K.K.		
	No.14 (G610 6F)	O1-am1-14	O1-am2-14			LS1-14 Incyte Japan G.K.		O1-pm1-14	O1-pm2-14		ES1-14 CSL Behring K.K.		
	No.15 (G701 7F)	O1-am1-15	O1-am2-15			LS1-15 Mallinckrodt Pharmaceuticals		O1-pm1-15 HSCT: GVHD/GVL 1 Chair : Tomomi Toubai	O1-pm2-15		ES1-15 ONO PHARMACEUTICAL CO., LTD.		
Online Seminar													
Digital Poster (Hall E B2F)	Poster Presentation (For details, please see the Digital Poster Program at a Glance.)				Poster Presentation (For details, please see the Digital Poster Program at a Glance.)								

Day 2 Saturday, October 14 Tokyo International Forum

Oral

MS : Morning Seminar
 LS : Luncheon Seminar
 ES : Evening Seminar
 IS : Industry Session
 O : Oral Session
 OLS : Online Seminar
 E : Lectures in English


Abstract Number Explanation
 Ex) O1-am1-7
 Oral Session Day1 - am 1st session - Room Number

	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00
Hall Building	No.1 (Hall C 4F)		JSH-EHA Joint Symposium Novel landscape of AML treatment Chairs : Hitoshi Kiyoi, Elizabeth Macintyre		ASH Special Lecture Chair : Kimuko Mitani Speaker : Robert Brodsky		LS2-1 Janssen Pharmaceutical K.K.	Plenary Session Chairs : Takanori Teshima, Akifumi Takaori-Kondo		Symposium 5 New technologies toward effective CAR-T cell therapy Chairs : Hiroshi Fujiwara, Yuki Kagoya		JSH Business Meeting
	No.2 (Hall B7(1) 7F)		Clinical Debate 1	Clinical Debate 2			LS2-2 Takeda Pharmaceutical Company Limited	Symposium 6 Clinical application of basic research in the field of thrombosis and hemostasis Chairs : Katsue Suzuki-Inoue, Yoshitaka Miyakawa				
	No.3 (Hall B7(2) 7F)	MS2-3 Janssen Pharmaceutical K.K.	EL2-3-1	EL2-3-2	EL2-3-3		LS2-3 Bristol Myers Squibb	EL2-3-4	EL2-3-5	EL2-3-6	ES2-3 Bristol Myers Squibb	
	No.4 (Hall B5(1) 5F)	MS2-4 Novartis Pharma K.K.	EL2-4-1	EL2-4-2	EL2-4-3		LS2-4 Novartis Pharma K.K.	EL2-4-4	EL2-4-5	EL2-4-6	ES2-4 Nippon Shinyaku Co., Ltd.	
	No.5 (Hall B5(2) 5F)	MS2-5 AbbVie GK	EL2-5-1	EL2-5-2	EL2-5-3		LS2-5 Gilead Sciences K.K.	EL2-5-4	EL2-5-5	EL2-5-6	ES2-5 Janssen Pharmaceutical K.K.	
	No.6 (Hall D7 7F)	MS2-6 Astellas Pharma Inc. Medical Affairs	O2-am1-6	O2-am2-6 DLBCL 3/MCL Chair : Hirohiko Shibayama			LS2-6 Chugai Pharmaceutical Co., Ltd.	O2-pm1-6 MM: Clinical Trials & Research 1 Chair : Yasushi Takamatsu		O2-pm2-6	ES2-6 Gilead Sciences K.K.	
	No.7 (Hall D5 5F)	MS2-7 Sanofi K.K.	O2-am1-7	O2-am2-7			LS2-7 Sanofi K.K.	O2-pm1-7	O2-pm2-7	ES2-7 Sanofi K.K.		
	No.8 (Hall D1 1F)	MS2-8 Takeda Pharmaceutical Company Limited	SETP 3 Myelodysplastic Syndrome/ Acute Myeloid Leukemia		SETP 4 Cellular Therapy		IS-8 Medical Affairs Division, Alexion Pharma GK	LS2-8 Alexion Pharma GK	O2-pm1-8 Hereditary Bone Marrow Failure Chair : Atsushi Narita	O2-pm2-8 Bone Marrow Failure/ Hemoglobinopathy Chair : Hideki Muramatsu	ES2-8 Takeda Pharmaceutical Company Limited	
Glass Building	No.9 (G402 4F)	MS2-9 Eisai Co., Ltd.	O2-am1-9	O2-am2-9 MM: Basic Research 2 Chair : Hideto Tamura			LS2-9 Pfizer Japan Inc.	O2-pm1-9	O2-pm2-9	ES2-9 Chugai Pharmaceutical Co., Ltd.		
	No.10 (G409 4F)	MS2-10 Nippon Shinyaku Co., Ltd.	O2-am1-10 ATL/HL: Clinical 1 Chair : Kenji Ishitsuka		O2-am2-10		LS2-10 AbbVie GK	O2-pm1-10 AML: Pathogenesis Chair : Issay Kitabayashi	O2-pm2-10 AML: Pathogenesis and Novel Therapeutic Targets Chair : Akihiko Yokoyama	ES2-10 AstraZeneca K.K.		
	No.11 (G502 5F)	MS2-11 Meiji Seika Pharma Co., Ltd.	O2-am1-11 ALL: Basic 1 Chair : Itaru Kato		O2-am2-11 ALL: Basic 2 Chair : Junko Takita		LS2-11 Sumitomo Pharma Co., Ltd.	O2-pm1-11	O2-pm2-11 CML: Clinical Research Chair : Eri Matsuki	ES2-11 Kyowa Kirin Co., Ltd.		
	No.12 (G510 5F)	MS2-12 Medical Science, PharmaEssentia Japan KK	O2-am1-12	O2-am2-12			LS2-12 Asahi Kasei Pharma Corporation	O2-pm1-12 Indolent B-cell Lymphoma: Clinical 3 Chair : Shinya Rai	O2-pm2-12	ES2-12 Novartis Pharma K.K.		
	No.13 (G602 6F)	MS2-13 MSD K.K. Medical Affairs	O2-am1-13	O2-am2-13 CNS Lymphoma 2/ IVLBCL 2 Chair : Eisei Kondo			LS2-13 ONO PHARMACEUTICAL CO., LTD.	O2-pm1-13 Malignant Lymphoma: Basic 1 Chair : Ai Kotani	O2-pm2-13	ES2-13 Sumitomo Pharma Co., Ltd.		
	No.14 (G610 6F)		O2-am1-14	O2-am2-14			LS2-14 Amgen K.K. / Astellas Pharma Inc.	O2-pm1-14	O2-pm2-14	ES2-14 MSD K.K.		
	No.15 (G701 7F)		O2-am1-15	O2-am2-15			LS2-15 MSD K.K.	O2-pm1-15	O2-pm2-15	ES2-15 ONO PHARMACEUTICAL CO., LTD.		
	Online Seminar						OLS2-1 Fujimoto Pharmaceutical Corporation					
Digital Poster (Hall E B2F)		Poster Presentation (For details, please see the Digital Poster Program at a Glance.)						Poster Presentation (For details, please see the Digital Poster Program at a Glance.)				


	8 : 00	9 : 00	10 : 00	11 : 00	12 : 00	13 : 00	14 : 00	15 : 00	16 : 00	17 : 00	18 : 00	19 : 00	
Hall Building	No.1 (Hall C 4F)		JSH-ASH Joint Symposium New pathophysiology in myelodysplastic syndromes Chairs : Hironori Harada, Robert Brodsky			EHA Special Lecture Chair : Itaru Matsumura Speaker : Elizabeth Macintyre	LS3-1 Genmab K.K. / AbbVie G.K.	JSH Award Lecture	Symposium 7 GVHD and GVL effect after allogeneic SCT Chairs : Ken-ichi Matsuoka, Hirohisa Nakamae			Closing Ceremony	
	No.2 (Hall B7(1) 7F)		Women Doctors Career Symposium				LS3-2 Sanofi K.K.		Symposium 8 Modern myeloid immunity Chairs : Tomohiko Tamura, Yoshio Katayama				
	No.3 (Hall B7(2) 7F)	MS3-3 Janssen Pharmaceutical K.K.	EL3-3-1	EL3-3-2	EL3-3-3		LS3-3 PharmaEssentia Japan KK	Special Symposium	Clinical Debate 3				
	No.4 (Hall B5(1) 5F)	MS3-4 Otsuka Pharmaceutical Co., Ltd.	EL3-4-1	EL3-4-2	EL3-4-3		LS3-4 Daiichi Sankyo Co., Ltd.	EL3-4-4	EL3-4-5	EL3-4-6			
	No.5 (Hall B5(2) 5F)	MS3-5 Chugai Pharmaceutical Co., Ltd.	EL3-5-1	EL3-5-2	EL3-5-3		LS3-5 Astellas Pharma Inc.	EL3-5-4	EL3-5-5	EL3-5-6			
	No.6 (Hall D7 7F)	MS3-6 Novartis Pharma K.K.	O3-am1-6 MM: Novel Immune & Cellular Therapy Chair : Yoichi Imai		O3-am2-6		LS3-6 Nippon Shinyaku Co., Ltd.	EL3-6-1	EL3-6-2				
	No.7 (Hall D5 5F)	MS3-7 ONO PHARMACEUTICAL CO., LTD./ Bristol-Myers Squibb K.K.	O3-am1-7	O3-am2-7			LS3-7 Otsuka Pharmaceutical Co., Ltd.	Public Symposium					
	No.8 (Hall D1 1F)	MS3-8 Sanofi K.K.	O3-am1-8 Hematopoietic Microenvironment Chair : Masanori Miyanishi		O3-am2-8	IS3-8 Bristol Myers Squibb Japan Medical	LS3-8 Eli Lilly Japan K.K.	O3-pm1-8		O3-pm2-8			
Glass Building	No.9 (G402 4F)	MS3-9 Asahi Kasei Pharma Corporation	O3-am1-9	O3-am2-9		LS3-9 argenx Japan K.K. Medical Affairs	O3-pm1-9	O3-pm2-9 AML: Epigenetics 2 Chair : Susumu Goyama					
	No.10 (G409 4F)	MS3-10 Medical HQs, Eisai Co., Ltd.	O3-am1-10 AML: Biomarker 1 Chair : Ayana Kon		O3-am2-10	LS3-10 Nippon Kayaku Co., Ltd.	O3-pm1-10	O3-pm2-10					
	No.11 (G502 5F)	MS3-11 Pfizer Japan Inc.	O3-am1-11	O3-am2-11		LS3-11 Takeda Pharmaceutical Company Limited	O3-pm1-11	O3-pm2-11					
	No.12 (G510 5F)	MS3-12 Takeda Pharmaceutical Company Limited	O3-am1-12	O3-am2-12		LS3-12 Medical Affairs Department, Torii Pharmaceutical Co., Ltd.	O3-pm1-12	O3-pm2-12 Bleeding Disorders Chair : Keiji Nogami					
	No.13 (G602 6F)		O3-am1-13	O3-am2-13		LS3-13 KISSEI PHARMACEUTICAL CO., LTD.	O3-pm1-13 Gene Therapy and Others Chair : Naoko Okochi		O3-pm2-13				
	No.14 (G610 6F)		O3-am1-14 HSCT: HSCT Outcomes/ Lymphoid Neoplasms Chair : Chikako Ohwada		O3-am2-14	LS3-14 AstraZeneca K.K.	O3-pm1-14 COVID-19 and Others Chair : Yasuo Mori		O3-pm2-14				
	No.15 (G701 7F)		O3-am1-15	O3-am2-15		LS3-15 Shionogi & Co., Ltd.	O3-pm1-15 Immunotherapy for B-cell lymphoma: Clinical Chair : Yasuyuki Arai		O3-pm2-15				
Online Seminar						OLS3-1 OHARA Pharmaceutical Co., Ltd.							
Digital Poster (Hall E B2F)		Poster Presentation (For details, please see the Digital Poster Program at a Glance.)					Poster Presentation (For details, please see the Digital Poster Program at a Glance.)						

Day 1 Friday, October 13 Tokyo International Forum **Digital Poster**

E : Session in English **E/J** : Session including presentation in English



Day 2 Saturday, October 14



Day 3 Sunday, October 15

